Results 91 to 100 of about 381,169 (287)

AKR1B10 in gastrointestinal diseases

Aging, 2015
Ulcerative colitis (UC) is characterized by long-standing mucosal inflammation of the large bowel, with increased tendency of developing colorectal cancer (CRC), i.e., colitis-associated cancer (CAC) [1]. The other two predisposing conditions for CRC are familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC), whose ...
Duan-Fang Liao, Yi Shen, Deliang Cao, Deliang Cao   +3 more
openaire   +3 more sources

Timing and Predictive Value of Clinical Conditions Preceding Multiple Sclerosis in the UK Biobank

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Multiple sclerosis (MS) patients often experience a higher incidence of clinical conditions before diagnosis, suggesting a prodromal phase. However, their predictive value and temporal trajectories remain underexplored. We investigated these aspects using the large UK Biobank's population‐based cohort, which provided clinical ...
Andrea Nova, Teresa Fazia, Giovanni Di Caprio, Davide Gentilini, Luisa Bernardinelli, Roberto Bergamaschi   +5 more
wiley   +1 more source

Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions [PDF]

, 2018
Eosinophilic gastrointestinal disorders are a set of conditions with a wide range of clinical manifestations and treatment modalities. The disorders are suspected to result from an abnormal inflammatory response to allergen(s), and individuals may ...
Gupta, Sandeep K., Naramore, Sara
core   +1 more source

Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein

Journal of Lipid Research, 1996
Mice in which the gene for mdr2 P-glycoprotein has been disrupted have a severe deficiency in biliary phospholipid and cholesterol secretion. We studied the relation between mdr2 gene expression and biliary lipid secretion with emphasis on the role of ...
R P Oude Elferink, R Ottenhoff, M van Wijland, C M Frijters, C van Nieuwkerk, A K Groen   +5 more
doaj  

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

Never events in gastrointestinal nursing [PDF]

, 2011
Gastrointestinal diseases and disorders frequently require interventions that can lead to serious consequences for patients when an organization has not put in place the correct systems and processes to prevent incidents from happening, procedures have ...
Cox, C. L.
core   +1 more source

Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis

Arthritis Care &Research, EarlyView.
Objective Our objective was to examine the relationship between colchicine plasma concentrations and clinical and demographic factors and to determine the relationship between colchicine concentrations and colchicine efficacy and colchicine‐specific adverse events.
Lisa K. Stamp, Anne Horne, Borislav Mihov, Jill Drake, Janine Haslett, Peter Chapman, Daniel F. B. Wright, Christopher Frampton, Nicola Dalbeth   +8 more
wiley   +1 more source

Establishing What Constitutes a Healthy Human Gut Microbiome: State of the Science, Regulatory Considerations, and Future Directions. [PDF]

, 2019
On December 17, 2018, the North American branch of the International Life Sciences Institute (ILSI North America) convened a workshop "Can We Begin to Define a Healthy Gut Microbiome Through Quantifiable Characteristics?" with >40 invited academic ...
Antonopoulos, Armitage, AVA, Singapore, Azad, Backhed, Barbara O Schneeman, Beaton, Beukers, Bindels, Bindels, Borewicz, Brazilian Health Regulatory Agency (ANVISA), Buddington, Cammarota, Campbell-Lendrum, Cantarel, Caporaso, Carlson, Cindy Davis, Claire M Fraser, Costea, Cummings, Curtis Huttenhower, Damen, Dao, David, David, Davis, Davoren, Desai, Deschasaux, Dethlefsen, De Preter, Earle, EFSA, EFSA, Eloe-Fadrosh, Esaiassen, European Commission, European Commission, Falony, FAO and WHO, FAO and WHO, FDA, FDA, FDA, FDA, FDA, FDA, FDA, FDA, FDA-NIH Biomarker Working Group, Fedacko, Fei, Ferretti, Fischbach, Flaherman, Flint, Forbes, Foster, Fragiadakis, Francois, François, François, Gibson, Government of Canada, Gregory, Gupta, Hadizadeh, He, Health Canada, Health Canada, Health Canada, Health Canada, Health Canada, Health Canada, Hermansson, Hildebrand, Ho, Holmes, Holmes, Holscher, Insel, Jacobsen, Jakobsson, Jangi, Janssens, Japan Consumer Affairs Agency, Japan Consumer Affairs Agency, Japan Ministry of Health, Labour, and Welfare, Japan Ministry of Health, Labour, and Welfare, Jens Walter, Jones, Kennedy, Koenig, Korpela, Kristensen, Kristin Verbeke, Kritchevsky, Krumbeck, Lahti, Lam, Langdon, Lawley, La Fata, Leiby, Lim, Lloyd-Price, Lohner, Lozupone, Makki, Maldonado-Gómez, Marcobal, Marie E Latulippe, Martin, Martinez, Martínez, Martínez, Martínez, Matamoros, McBurney, McBurney, McBurney, McFarland, Michael I McBurney, Miller, MOH Malaysia, MOH Malaysia, MOPH Thailand, Mould, Mueller, NDAC, Palleja, Perez-Muñoz, Rattanaprasert, Roager, Robb, Rothschild, Round, Russell, Rutishauser, Saxelin, Schloissnig, Schlomann, Schneeberger, Schroeder, Snijder, Song, Sonnenburg, Sonnenburg, Sprockett, Sundin, Surana, Tanemura, Tannock, Taverniti, The Human Microbiome Project Consortium, Tremlett, Trowell, Vandeputte, Vangay, Vatanen, Vellend, Venkataraman, Venkataraman, Voigt, von Wintzingerode, Walter, Wan, Wang, Watson, Wedekind, Windey, Windey, Windey, Wong, Wu, Yassour   +177 more
core   +2 more sources

Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective Gastrointestinal perforation (GIP) is a rare and life‐threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta‐analysis approach.
Thipsukhon Sathapanasiri, Manuel Meraz, Hamraz Mokri, Sajesh K Veettil, Karn Wijarnpreecha, Naomi Schlesinger, Arthur Kavanaugh, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source

Advanced Oropharyngeal Cancer Can Be Easily Missed During Esophagogastroduodenoscopy

European Journal of Case Reports in Internal Medicine, 2017
The case of an elderly man with an advanced oropharyngeal cancer that was missed during esophagogastroduodenoscopy is described. He was referred for endoscopic resection of superficial esophageal squamous cell neoplasms.
Kenta Hamada, Tomofumi Akasaka, Yasushi Yamasaki, Ryu Ishihara   +3 more
doaj   +1 more source